Cargando…

Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review

PURPOSE: Testicular germ cell tumours (GCTs) represent the most common malignancy in young adult males with two thirds of all cases presenting with clinical stage I (CSI). Active surveillance is the management modality mostly favoured by current guidelines. This systematic review assesses the treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruf, Christian G., Schmidt, Stefanie, Kliesch, Sabine, Oing, Christoph, Pfister, David, Busch, Jonas, Heinzelbecker, Julia, Winter, Christian, Zengerling, Friedemann, Albers, Peter, Oechsle, Karin, Krege, Susanne, Lackner, Julia, Dieckmann, Klaus-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712330/
https://www.ncbi.nlm.nih.gov/pubmed/36107211
http://dx.doi.org/10.1007/s00345-022-04145-6
_version_ 1784841763279601664
author Ruf, Christian G.
Schmidt, Stefanie
Kliesch, Sabine
Oing, Christoph
Pfister, David
Busch, Jonas
Heinzelbecker, Julia
Winter, Christian
Zengerling, Friedemann
Albers, Peter
Oechsle, Karin
Krege, Susanne
Lackner, Julia
Dieckmann, Klaus-Peter
author_facet Ruf, Christian G.
Schmidt, Stefanie
Kliesch, Sabine
Oing, Christoph
Pfister, David
Busch, Jonas
Heinzelbecker, Julia
Winter, Christian
Zengerling, Friedemann
Albers, Peter
Oechsle, Karin
Krege, Susanne
Lackner, Julia
Dieckmann, Klaus-Peter
author_sort Ruf, Christian G.
collection PubMed
description PURPOSE: Testicular germ cell tumours (GCTs) represent the most common malignancy in young adult males with two thirds of all cases presenting with clinical stage I (CSI). Active surveillance is the management modality mostly favoured by current guidelines. This systematic review assesses the treatment results in CSI patients concerning recurrence rate and overall survival in non-seminoma (NS) and pure seminoma (SE) resulting from surveillance in comparison to adjuvant strategies. METHODS/SYSTEMATIC REVIEW: We performed a systematic literature review confining the search to most recent studies published 2010–2021 that reported direct comparisons of surveillance to adjuvant management. We searched Medline and the Cochrane Library with additional hand-searching of reference lists to identify relevant studies. Data extraction and quality assessment of included studies were performed with stratification for histology (NS vs. SE) and treatment modalities. The results were tabulated and evaluated with descriptive statistical methods. RESULTS: Thirty-four studies met the inclusion criteria. In NS patients relapse rates were 12 to 37%, 0 to 10%, and 0 to 11.8% for surveillance, chemotherapy and for retroperitoneal lymph node dissection (RPLND) while overall survival rates were 90.7−100%, 91.7−100%, and 97−99.1%, respectively. In SE CSI, relapse rates were 0−22.3%, 0−5%, and 0−12.5% for surveillance, radiotherapy, chemotherapy, while overall survival rates were 84.1−98.7%, 83.5−100%, and 92.3−100%, respectively. CONCLUSION: In both histologic subgroups, active surveillance offers almost identical overall survival as adjuvant management strategies, however, at the expense of higher relapse rates. Each of the management strategies in CSI GCT patients have specific merits and shared-decision-making is advised to tailor treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-022-04145-6.
format Online
Article
Text
id pubmed-9712330
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-97123302022-12-02 Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review Ruf, Christian G. Schmidt, Stefanie Kliesch, Sabine Oing, Christoph Pfister, David Busch, Jonas Heinzelbecker, Julia Winter, Christian Zengerling, Friedemann Albers, Peter Oechsle, Karin Krege, Susanne Lackner, Julia Dieckmann, Klaus-Peter World J Urol Topic Paper PURPOSE: Testicular germ cell tumours (GCTs) represent the most common malignancy in young adult males with two thirds of all cases presenting with clinical stage I (CSI). Active surveillance is the management modality mostly favoured by current guidelines. This systematic review assesses the treatment results in CSI patients concerning recurrence rate and overall survival in non-seminoma (NS) and pure seminoma (SE) resulting from surveillance in comparison to adjuvant strategies. METHODS/SYSTEMATIC REVIEW: We performed a systematic literature review confining the search to most recent studies published 2010–2021 that reported direct comparisons of surveillance to adjuvant management. We searched Medline and the Cochrane Library with additional hand-searching of reference lists to identify relevant studies. Data extraction and quality assessment of included studies were performed with stratification for histology (NS vs. SE) and treatment modalities. The results were tabulated and evaluated with descriptive statistical methods. RESULTS: Thirty-four studies met the inclusion criteria. In NS patients relapse rates were 12 to 37%, 0 to 10%, and 0 to 11.8% for surveillance, chemotherapy and for retroperitoneal lymph node dissection (RPLND) while overall survival rates were 90.7−100%, 91.7−100%, and 97−99.1%, respectively. In SE CSI, relapse rates were 0−22.3%, 0−5%, and 0−12.5% for surveillance, radiotherapy, chemotherapy, while overall survival rates were 84.1−98.7%, 83.5−100%, and 92.3−100%, respectively. CONCLUSION: In both histologic subgroups, active surveillance offers almost identical overall survival as adjuvant management strategies, however, at the expense of higher relapse rates. Each of the management strategies in CSI GCT patients have specific merits and shared-decision-making is advised to tailor treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-022-04145-6. Springer Berlin Heidelberg 2022-09-15 2022 /pmc/articles/PMC9712330/ /pubmed/36107211 http://dx.doi.org/10.1007/s00345-022-04145-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Topic Paper
Ruf, Christian G.
Schmidt, Stefanie
Kliesch, Sabine
Oing, Christoph
Pfister, David
Busch, Jonas
Heinzelbecker, Julia
Winter, Christian
Zengerling, Friedemann
Albers, Peter
Oechsle, Karin
Krege, Susanne
Lackner, Julia
Dieckmann, Klaus-Peter
Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review
title Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review
title_full Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review
title_fullStr Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review
title_full_unstemmed Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review
title_short Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review
title_sort testicular germ cell tumours’ clinical stage i: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review
topic Topic Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712330/
https://www.ncbi.nlm.nih.gov/pubmed/36107211
http://dx.doi.org/10.1007/s00345-022-04145-6
work_keys_str_mv AT rufchristiang testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT schmidtstefanie testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT klieschsabine testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT oingchristoph testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT pfisterdavid testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT buschjonas testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT heinzelbeckerjulia testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT winterchristian testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT zengerlingfriedemann testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT alberspeter testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT oechslekarin testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT kregesusanne testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT lacknerjulia testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview
AT dieckmannklauspeter testiculargermcelltumoursclinicalstageicomparisonofsurveillancewithadjuvanttreatmentstrategiesregardingrecurrenceratesandoverallsurvivalasystematicreview